Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGM:PAHC
NasdaqGM:PAHCPharmaceuticals

Stronger Q2 Results And 2026 Outlook Might Change The Case For Investing In Phibro Animal Health (PAHC)

In early February 2026, Phibro Animal Health reported second-quarter 2026 results showing sales of US$373.91 million and net income of US$27.46 million, alongside six‑month sales of US$737.8 million and net income of US$53.99 million, all significantly higher than a year earlier. At the same time, the company issued fiscal 2026 guidance calling for net sales of US$1.45–US$1.50 billion and diluted EPS of US$2.08–US$2.32, giving investors a clearer view of expected scale and profitability for...
OM:BIOG B
OM:BIOG BBiotechs

Assessing BioGaia (OM:BIOG B) Valuation After Earnings Growth And Dividend Changes

What the latest results and dividend moves mean for BioGaia shareholders BioGaia (OM:BIOG B) has attracted fresh attention after reporting fourth quarter and full year 2025 earnings, alongside a proposed reduction in its ordinary dividend and a separate extra dividend plan. See our latest analysis for BioGaia. At a share price of SEK102.8, BioGaia has had a 30 day share price return of 8.13% decline and a 1 year total shareholder return of 17.38% decline, while the 5 year total shareholder...
NYSE:GKOS
NYSE:GKOSMedical Equipment

Assessing Glaukos (GKOS) Valuation After Strong Growth Guidance And Intangible Asset Impairment

Glaukos (GKOS) has drawn fresh attention after reporting fourth quarter and full year 2025 results, issuing 2026 sales guidance of US$600 million to US$620 million, and recording a US$112,867,000 intangible asset impairment. See our latest analysis for Glaukos. Despite the latest guidance and impairment announcement, Glaukos’ recent trading has been weaker, with a 1 month share price return of 11.31% and a 1 year total shareholder return decline of 30.28%. However, the 3 year total...
NYSEAM:UAMY
NYSEAM:UAMYMetals and Mining

Why United States Antimony (UAMY) Is Down 11.0% After Idaho Antimony JV Deal With Americas Gold

On 10 February 2026, Americas Gold and Silver Corporation announced a definitive joint venture agreement with United States Antimony to build and operate a new antimony processing plant in Idaho’s Silver Valley, with Americas holding 51% and US Antimony 49% ownership. This partnership links Americas’ mine feed from the Galena Complex with US Antimony’s processing and marketing capabilities, creating a fully U.S.-based mine-to-finished antimony supply chain that could align with federal...
NYSE:AVTR
NYSE:AVTRLife Sciences

Is Avantor (AVTR) Offering Value After Steep Multi‑Year Share Price Declines?

If you are wondering whether Avantor's share price now reflects good value or lingering risk, you are not alone. The stock recently closed at US$9.05, with returns of an 18.9% decline over 7 days, a 25.6% decline over 30 days, a 21.0% decline year to date, a 47.8% decline over 1 year, a 62.6% decline over 3 years, and a 67.7% decline over 5 years. Recent coverage of Avantor has focused on its role in the broader pharmaceuticals and biotech supply chain and how sentiment around the sector may...
NYSE:SPGI
NYSE:SPGICapital Markets

S&P Global Highlights Climate And Liquidity Analytics Opportunity For Investors

S&P Global (NYSE:SPGI) announced a collaboration with Verisk to share climate catastrophe exposure data for financial and insurance clients. The company also released its 2026 Liquidity Outlook, focusing on credit market risks tied to private credit, technology sector issuance related to AI, and potential changes in Federal Reserve policy. S&P Global, known for its credit ratings, benchmarks, and risk analytics, is leaning further into climate and credit risk data as investors and lenders...
NasdaqGS:EXE
NasdaqGS:EXEOil and Gas

Is Expand Energy (EXE) Pricing Reflect Long Term Cash Flow Forecasts After Recent Reassessment?

If you are wondering whether Expand Energy is still worth your attention at around US$102.75, the key question is how that price stacks up against the company’s underlying value. The stock has been relatively steady in the short term, with returns of 0.5% over the last 7 days and 2.9% over the last 30 days, while year to date it is down 6.4% and the 1 year return is a marginal 0.4%, set against a 46.1% 3 year return and a 195.9% 5 year return. Recent news coverage around Expand Energy has...
NYSE:NFG
NYSE:NFGGas Utilities

Is It Too Late To Consider National Fuel Gas (NFG) After Its Strong 5 Year Run?

If you are wondering whether National Fuel Gas is still reasonably priced after its run, this breakdown will help you work out what you are really paying for today. The stock most recently closed at US$87.17, with reported returns of 2.7% over 7 days, 7.3% over 30 days, 6.2% year to date, 22.3% over 1 year, 70.9% over 3 years and 123.3% over 5 years. Recent coverage has focused on how National Fuel Gas fits into the wider US utilities sector and how investors are thinking about regulated...
TSE:1801
TSE:1801Construction

The Bull Case For Taisei (TSE:1801) Could Change Following Profit Growth Amid Falling Revenue – Learn Why

Taisei Corporation recently reported earnings for the nine months ended December 31, 2025, with revenue of ¥1,427,758 million versus ¥1,527,540 million a year earlier, while net income rose to ¥102,568 million from ¥83,770 million. Despite lower revenue, Taisei’s basic earnings per share from continuing operations increased from ¥457.17 to ¥615.38, highlighting stronger profitability over the period. Next, we’ll examine how Taisei’s higher earnings per share, achieved despite revenue...
NYSE:SNOW
NYSE:SNOWIT

Snowflake OpenAI Deal Puts AI Growth Story Against Weak Share Momentum

Snowflake (NYSE:SNOW) has agreed a $200 million partnership with OpenAI to bring OpenAI models into its Cortex AI platform. The company launched Cortex Code, a coding agent aimed at helping developers build on Snowflake more efficiently. Snowflake also announced new enterprise AI deployments with clients including United Rentals and Wolfspeed. For investors watching NYSE:SNOW, this AI push lands at a time when the shares trade around $177.1 and recent returns have been mixed. The stock...
NYSE:CBZ
NYSE:CBZProfessional Services

Is CBIZ’s (CBZ) New Buyback Plan Reframing Its Capital Allocation Strategy or Simply Staying the Course?

In February 2026, CBIZ, Inc. announced a new share repurchase program authorizing the buyback of up to 5,000,000 shares through March 31, 2027, funded by operating cash flow and its credit facility following the expiration of its prior plan. This renewed commitment to returning capital highlights management’s confidence in CBIZ’s cash generation and balance sheet flexibility even as it continues to fund growth initiatives. We’ll now examine how this newly authorized, debt-supported...
NYSE:JBL
NYSE:JBLElectronic

Is Jabil (JBL) Still Attractive After Multi‑Year Surge And Fresh DCF Valuation?

If you are wondering whether Jabil's current share price reflects its underlying value, this article will walk you through what the numbers actually say. Jabil shares last closed at US$257.40, with returns of a 0.6% decline over 7 days, 2.4% over 30 days, 7.1% year to date, 51.7% over 1 year and a very large gain over 5 years. Recent headlines around Jabil have focused on its position as a key manufacturing partner for large electronics and industrial customers, as well as ongoing portfolio...
NYSE:BANC
NYSE:BANCBanks

A Look At Banc Of California (BANC) Valuation As Recent Returns Draw Investor Attention

Why Banc of California is on investors’ radar today Banc of California (BANC) is drawing attention after recent share price moves, with the stock last closing at $20.10. Investors are weighing this level against the bank’s current earnings profile and valuation signals. See our latest analysis for Banc of California. At the current share price of $20.10, Banc of California’s recent 18.93% 3 month share price return and 29.49% 1 year total shareholder return suggest momentum has improved...
NasdaqGM:OCUL
NasdaqGM:OCULPharmaceuticals

Is It Time To Reassess Ocular Therapeutix (OCUL) After The Recent Share Price Slump

If you are trying to figure out whether Ocular Therapeutix at around US$6.99 still offers value or has run its course, you are in the right place. The stock has recently been volatile, with a 22.6% decline over the last 7 days, a 38.0% decline over 30 days and a 40.9% decline year to date, while the 3 year return sits at 21.8%. Recent headlines around Ocular Therapeutix have focused on its position in ophthalmology and how its pipeline and products could shape future prospects. This helps...
BME:COXG
BME:COXGRenewable Energy

3 European Stocks Estimated To Be Up To 47.9% Below Intrinsic Value

As European markets navigate volatility and digest global economic data, the pan-European STOXX Europe 600 Index recently reached a new high before settling with a modest gain. Amid these fluctuating conditions, identifying undervalued stocks can be crucial for investors seeking potential opportunities; such stocks may offer value by trading below their intrinsic worth despite broader market challenges.